Mutations such as JAK2 V617F, while more commonly associated with myeloproliferative neoplasms, have also been implicated in pediatric leukemia subtypes, including acute lymphoblastic leukemia and acute myeloid leukemia. Here, JAK2 is linked to myeloproliferative disorder.